JPS63115815A - Hepatic disease remedy composition - Google Patents
Hepatic disease remedy compositionInfo
- Publication number
- JPS63115815A JPS63115815A JP25965086A JP25965086A JPS63115815A JP S63115815 A JPS63115815 A JP S63115815A JP 25965086 A JP25965086 A JP 25965086A JP 25965086 A JP25965086 A JP 25965086A JP S63115815 A JPS63115815 A JP S63115815A
- Authority
- JP
- Japan
- Prior art keywords
- cyclodextrin
- tritoqualine
- tritoqualin
- composition
- crystalline cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 208000019423 liver disease Diseases 0.000 title claims description 8
- IRGJVQIJENCTQF-UHFFFAOYSA-N tritoqualine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=C(OCC)C(OCC)=C(OCC)C(N)=C2C(=O)O1 IRGJVQIJENCTQF-UHFFFAOYSA-N 0.000 claims abstract description 35
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 9
- 229920002678 cellulose Polymers 0.000 claims abstract description 9
- 239000001913 cellulose Substances 0.000 claims abstract description 9
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 4
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 5
- 235000012239 silicon dioxide Nutrition 0.000 claims description 5
- 229940126585 therapeutic drug Drugs 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 abstract description 6
- 229960002634 tritoqualine Drugs 0.000 abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 3
- 238000000227 grinding Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000010828 elution Methods 0.000 abstract 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- 241000283986 Lepus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000009253 Morus australis Species 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
（産業上の利用分野）
本発明は、肝疾患治療薬として有用なトリトクプリン含
有組成物に関する。さらに詳しくはトリトクアリンの水
に対する溶解速度を高めたトリトクアリン含有組成物に
関する。DETAILED DESCRIPTION OF THE INVENTION (Industrial Field of Application) The present invention relates to a tritocuprine-containing composition useful as a therapeutic agent for liver diseases. More specifically, the present invention relates to a tritoqualin-containing composition in which the dissolution rate of tritoqualin in water is increased.
（従来の技術）
トリトクアリｙ （Ｔｒｉｔｏｑｕａｌｉｎｅ ） ハ
、下記間造式（１）で示される７−アミノ−４ｔ、Ｊ’
、４− ）リエトキシーＪ−（ｊ、ｔ、７．？−テトラ
ヒドロ−ターメトキシ−６−メチル−／、３−ジオキソ
口（４ｔ、ｔ−ｙ〕イソキノリン−！−イル）フタライ
ド（’ｚａ”、ＮｔＯｓ ）であり、トリトカリン（Ｔ
ｒ１士ｏｃａｌｉｎｅ ）又はハイボスタミ：／ （Ｈ
ｙｐｏ−ｓｔａｍｉｎｅ ）とも呼ばれる。(Prior art) Tritoqualine 7-amino-4t, J' represented by the following formula (1)
, 4-) Liethoxy J-(j, t, 7.?-tetrahydro-termethoxy-6-methyl-/, 3-dioxo(4t, ty] isoquinolin-!-yl) phthalide ('za', NtOs ) and tritocalin (T
r1shiocaline) or highbostami:/ (H
Also called ypo-stamine).
トリトクアリンは、ヨーロッパでは抗アレルギー剤とし
て使用されているが、最近肝疾患の治療に有効であるこ
とが見い出された。Tritoqualin is used in Europe as an anti-allergic agent, but has recently been found to be effective in treating liver disease.
（発明が解決しようとする問題点）
しかしながら、このトリトクアリンは水に対して難溶性
であシ、固形展剤とした待合、その溶出性が急く、バイ
オアベイラビリティ−（Ｂｉｏａｖａｉｌａｂｉｌｉｔ
ｙ、 生物学的利用性）が低いという欠点があった。(Problems to be Solved by the Invention) However, this tritoqualin is poorly soluble in water, and when used as a solid excipient, its dissolution is rapid and its bioavailability is poor.
y, bioavailability) was low.
（問題点を解決するための手段）
本発明者らは、トリトクアリンの組成物における上記の
欠点を解消するために鋭意研死な重ねた結果、結晶性セ
ルロース、シクロデキストリン、メチル化シクロデキス
トリン、軽質無水ケイ酸、合成ケイ酸アルミニウム及び
メタケイ酸アルミン酸マグネシウムよ）なる群から選ば
几る７棟又は２種以上とトリトクアリンとを混合粉砕す
ることによシ、著しく溶出性の改善が図れることと共に
、持続的な過飽和現象を呈することを見出し、本発明に
到達した。(Means for Solving the Problems) As a result of extensive efforts by the present inventors to eliminate the above-mentioned drawbacks in tritoqualin compositions, the present inventors have discovered that crystalline cellulose, cyclodextrin, methylated cyclodextrin, light anhydrous By mixing and pulverizing tritoqualin with 7 or more selected from the group consisting of silicic acid, synthetic aluminum silicate, and magnesium aluminate metasilicate, it is possible to significantly improve dissolution properties and to maintain The present invention was achieved based on the discovery that a supersaturation phenomenon occurs.
すなわち本発明の要旨は結晶性セルロース、シクロデキ
ストリン、メチル化シクロデキストリン、軽質無水ケイ
酸、合成ケイ酸アルミニウム及びメタケイ酸アルミン酸
マグネシウムよりなる群から選ばれる７種又は２種以上
とトリトクアリンとを混合粉砕せしめることにより得ら
れる肝疾患治療梁組放物に存する。以下本発明の詳細な
説明する。That is, the gist of the present invention is to mix tritoqualin with seven or more selected from the group consisting of crystalline cellulose, cyclodextrin, methylated cyclodextrin, light anhydrous silicic acid, synthetic aluminum silicate, and magnesium aluminate metasilicate. The treatment for liver diseases consists in the beam set parabolite obtained by crushing it. The present invention will be explained in detail below.
本発明において、混合粉砕に用いる装置は本発明におけ
る混合粉砕を達成できるものであれば何ら制限されない
が、振動ミル及びボールミルを用いて数分〜数時間程度
、好適には被初砕物が非晶質化するまで粉砕するのが良
い。In the present invention, the device used for mixed pulverization is not limited in any way as long as it can achieve the mixed pulverization in the present invention, but it is preferable to use a vibrating mill or a ball mill for several minutes to several hours until the material to be initially crushed is amorphous. It is best to crush it until it becomes solid.
この混合粉砕法に用いる結晶性セルロース、シクロデキ
ストリン、メチル化シクロテキストリン、軽質無水ケイ
酸、合成ケイ酸アルミニウム及びメタケイ酸アルミン酸
マグネシウムよりなる群から選ばれる／ａＩ又は、２種
以上の便用量は、トリトクアリン／重量部に対して１〜
１０重量部好ましくは一〜９ｉ量部が適当である。A stool dose of /aI or two or more selected from the group consisting of crystalline cellulose, cyclodextrin, methylated cyclotextrin, light anhydrous silicic acid, synthetic aluminum silicate, and magnesium aluminate metasilicate used in this mixed grinding method. is 1 to 1 to tritoqualin/part by weight.
10 parts by weight, preferably 1 to 9 parts by weight, is suitable.
本発明で得られるトリトクアリンの組成物は、それ自体
で用いることもできるし、また、他に薬理学的に許容さ
れる／８ｉ又は２種以上の適当な担体、賦形剤、結合剤
、滑沢剤、崩壊剤、その他と混合し、粉末（成剤）、顆
粒剤、錠剤、カプセル剤、坐剤等の製剤として経口的又
は経粘膜的に投与することができる。The tritoqualin composition obtained in the present invention can be used by itself, or can be used in combination with pharmacologically acceptable /8i or two or more suitable carriers, excipients, binders, and lubricants. It can be mixed with a lubricant, a disintegrant, and others and administered orally or transmucosally in the form of a powder, granule, tablet, capsule, suppository, or other preparation.
トリトクアリンの投与量は、通常、成人／日当シフ０−
コ、０００岬程度が採用される。The dosage of tritoqualin is usually 0-100 mg per day per adult.
Approximately 000 capes will be adopted.
（実施ｆ！Ｉ ）
以下、実施例を挙げて本発明を更に具体的に説明するが
、本発明はその要旨を越えない限シ以下の実施例によっ
て限定されるものではない。(Implementation f!I) The present invention will be described in more detail below with reference to Examples, but the present invention is not limited to the following Examples as long as the gist thereof is not exceeded.
実施例／
トリトクアリンθ、／と結晶性セルロース（″アビセル
ＰＨ１０／”） ３．．２ｇを振動ロッドミル（平工製
作ＰＪＴｆｉ）でλθ分間混合粉砕しトリトクアリン組
成物を得た。Example/ Tritoqualin θ,/ and crystalline cellulose ("Avicel PH10/") 3. ．． 2 g was mixed and pulverized for λθ minutes using a vibrating rod mill (PJTfi manufactured by Heiko Seisakusho) to obtain a tritoqualin composition.
上記で得られた組成物及びトリトクアリンと結晶性セル
ロースとの／二４ｔ（重量比）混合物（比較例）につき
粉末Ｘ線回析の測定（１０ｏ。Measurement of powder X-ray diffraction (10o) for the composition obtained above and a /24t (weight ratio) mixture of tritoqualin and crystalline cellulose (comparative example).
ａｐｅ、ガラスセル）を行ったところ、混合粉砕したも
ののみ結晶性ピークが認められなかった。ape, glass cell), no crystalline peak was observed only in the mixed and pulverized product.
すなわち混合粉砕によｆｉ）リトクアリンが無定形とな
ったことが確認された。That is, it was confirmed that fi) lithoqualin became amorphous by mixing and pulverization.
実施例−
トリトクアリンｏ、４ｔｇと結晶性セルロース（Ｉ″ア
ビセルＰＨ１０／） ３．ｔ ｇを用い、以下実施例／
と同様にしてトリトクアリン組成物を得た。該組成物の
Ｘ線回折では、トリトクアリンの結晶性ピークは認めら
汎なかった。Example - The following Example/
A tritoqualin composition was obtained in the same manner as above. In X-ray diffraction of the composition, no crystalline peak of tritoqualin was observed.
実施例３
トリトクアリンｏ、ｔｒｙとβ−シクロデキストリン３
１．２ ｌを振動ロッドミルで！分間、混合粉砕しトリ
トクアリン組成物を得た。Example 3 Tritoqualin o, try and β-cyclodextrin 3
1.2 liters with a vibrating rod mill! The mixture was mixed and ground for a few minutes to obtain a tritoqualin composition.
上記で得られた組成物及びトリトクアリンとβ−シクロ
デキストリンとの／：４ｔ（重量比）混合物（比較例）
につき、粉末ｘｉ回析の測定（１０００ｃｐｓ、ガラス
セル）を行ったところ上記組成物についてのみトリトク
アリンの結晶性ピークは認められなかった。The composition obtained above and a /:4t (weight ratio) mixture of tritoqualin and β-cyclodextrin (comparative example)
When powder xi diffraction was measured (1000 cps, glass cell), no crystalline peak of tritoqualin was observed only for the above composition.
実施例ク
トリトクアリン０．４ｔ ９とβ−シクロテキストリン
Ｊ、Ａ Ｉを用い以下実施例３と同様にして、トリトク
アリン組成物を得た。該組成物のＸ線回析では、トリト
クアリンの結晶性ピークは認められなかった。Example A tritoqualin composition was obtained in the same manner as in Example 3 using 0.4t 9 of tritoqualin and β-cyclotextrin J and AI. In X-ray diffraction of the composition, no crystalline peak of tritoqualin was observed.
試験例／
第１／改正日本桑局方の俗出試験法第λ法（パドル法）
に従い、実施例／〜グによシ得られた本発明のトリトク
アリン組成物の溶出性を試験した。試験液には、ｐｋｌ
４１．０のブリトン−とし、各組成物は１０メツシユ
パスの粉末でトリトクプリンとして１００ｎｆ相当量添
加した。Test example / 1st / Revised Japanese Mulberry Pharmacopoeia popular test method λ method (paddle method)
Accordingly, the dissolution properties of the tritoqualin compositions of the present invention obtained in Examples/-- were tested. The test solution contains pkl
41.0 Briton, and each composition was added in an amount equivalent to 100 nf as tritocuprine in the form of 10 mesh powder.
マドグラフィー（ＨＰＬＯ）法でトリトクアリン濃度を
測定した。The tritoqualin concentration was measured by the HPLO method.
対照としてｉηづッーパユしたトリトクアリン微細化品
を用込て、同様に試験した。As a control, the same test was carried out using a tritoqualin micronized product that had been subjected to iη-spraying.
結果を第１：Ａ及び第１図に示す。The results are shown in Section 1:A and FIG.
第１表
（発明の効果）
第１表及び第１図よシ明らかなように本発明によれば、
バイオアベイラビリティ−の向上した肝疾患治療薬を提
供することができる。Table 1 (Effects of the Invention) As is clear from Table 1 and FIG. 1, according to the present invention,
A liver disease therapeutic drug with improved bioavailability can be provided.
第１図は、実施例２（○で示す）及び実施例４ｔ（・で
示す）で得られる本発明の組成物ならびに対照であるト
リトクアリン原末（Δで示す〕の溶解挙動を示す図であ
る。図中で縦軸は、溶解トリトクアリンの濃度、横軸は
時間を表わし、また点憩（−−−−−）は飽和濃度を示
す。
出 願 人 三菱化成工業株式会社
代 理 人 弁理士 長谷用 −
ほか７名
駒間（勿）
手続補正書（自発）
昭和６２年３り／／日
１ 事件の表示 昭和ｚ７年特 許 項第Ｊｊ９ｊｊθ
号２発 明 の名称 肝疾患治療薬組成物３ 補正をす
る者
出願人 （ｊ９ｊ）三菱化成工業株式会社４代理人〒１
００
東京都千代田区丸の内二丁目５番２号
（ほか ｌ 名）
５ 補正の対象 明細書の「発明の詳細な説明」の欄
６ 補正の内容
（１） 明細書第３頁第６行に「暗合」とあるを「場
合」と訂正する。
（自発）手続補正書
昭和６コ年 ヲ月／Δ日
１ 事件の表示 昭和６７年 特許 願第コｔ９１ｔＯ
号２ 発明 の名称 肝疾患治療薬組成物３ 補正を
する者
出願人（ｔ９Ｘ）三菱化成工業株式会社４代理人〒１０
０
東京都千代田区丸の内二丁目５′ａ２号５ 補正の対象
明＃１番の「発明の詳細な説明」の欄６補正の内容
（１） 明細曹第を頁第１表と下から第グ行の「（発
明の効果）」との間に以下の文を挿入する。
７４π＼
「試験例コ
ビーグル犬（雄、／／−／ｊＡ：９）４頭に。
実施例／で得た本発明の組成物を投与し、経時的に血中
濃度を測定した。
投与量は、ピーグル犬１頭に対し、トリトクワリ７１０
０キとし、飼料２００１１を食べさせ７５３０分後に投
与した。
投与後Ｏ１タ、１％コ、ｊ、 ＠、Ａ及びＳ 時間に各
Ｊｓｄ採血し、血漿中のトリトリワリンａ［を高速液体
クロマトグラフィー
（ＨＰＬＣ）法で測定し几。比較例として。
１００メツシ凰パスしたトリトクワリン微細化品を用い
て、同様に試験した０その結第λ表 本願組成物のバイ
オアベイラビリティ−パラメーター
（各数値は ！±Ｊ３．Ｅ、を示す。）ｃｍａｘ ：
最高血中濃度
Ｔｍａｘ ： 最高血中濃度到達時間
＊ＶＣ：血中濃度−時間曲線下面積
ＡＵＣ＝パ：ｃａｉＪ
（２） 明細書第ざ頁下から第３行Ｋ「第１表」とあ
る後Ｋ「、第１表」を挿入する０
以 上FIG. 1 is a diagram showing the dissolution behavior of the compositions of the present invention obtained in Example 2 (indicated by ○) and Example 4t (indicated by .) and the control tritoqualin bulk powder (indicated by Δ). In the figure, the vertical axis represents the concentration of dissolved tritoqualin, the horizontal axis represents time, and the dotted lines (------) represent the saturated concentration. Applicant Mitsubishi Chemical Industries, Ltd. Representative Patent Attorney Hase - 7 others Komama (Mazu) Procedural amendment (voluntary) March 1, 1988 1 Display of case 1988 patent Section Jj9jjθ
Invention No. 2 Name of the invention Liver disease therapeutic composition 3 Amendment applicant Applicant (j9j) Mitsubishi Chemical Industries, Ltd. 4 Agent 〒1
00 2-5-2 Marunouchi, Chiyoda-ku, Tokyo (and other names) 5 Subject of amendment Column 6 of “Detailed Description of the Invention” of the specification 6 Contents of amendment (1) In the 6th line of page 3 of the specification: “ Correct the word ``conjunction'' to ``case''. (Voluntary) Procedural Amendment 1939 Month/Date 1 Case Indication 1988 Patent Application No. 91tO
No. 2 Title of the invention Liver disease therapeutic composition 3 Amendment person Applicant (t9X) Mitsubishi Chemical Industries, Ltd. 4 Agent Address: 10
0 No. 5'a2, 2-chome Marunouchi, Chiyoda-ku, Tokyo Subject of amendment Contents of amendment in column 6 of "Detailed explanation of the invention" of Akira No. 1 (1) Detailed description No. Insert the following sentence between the line "(effect of the invention)". 74π\ "Test Example: Four cobeagle dogs (male, //-/jA: 9) were administered the composition of the present invention obtained in Example/, and the blood concentration was measured over time. , 710 tritokwari for one peagle dog
The animals were fed with feed 20011 and administered 7,530 minutes later. After administration, blood was collected at 1, 1%, 1%, 1%, 1%, 1%, 1%, 1%, 1%, 1%, and 1% of each Jsd, and tritriwalin a in the plasma was measured using high performance liquid chromatography (HPLC). As a comparative example. Table λ Bioavailability parameters of the composition of the present invention (each numerical value indicates !±J3.E) cmax:
Maximum blood concentration Tmax: Time to reach maximum blood concentration * VC: Area under the blood concentration-time curve AUC = PA: caiJ (2) After the description “Table 1” in the third line K from the bottom of page 3 of the specification Insert K ", Table 1" 0 or more
Claims (2)
化シクロデキストリン、軽質無水ケイ酸、合成ケイ酸ア
ルミニウム及びメタケイ酸アルミン酸マグネシウムより
なる群から選ばれる１種又は２種以上とトリトクアリン
とを混合粉砕せしめることにより得られる肝疾患治療薬
組成物。(1) Mixing and pulverizing one or more selected from the group consisting of crystalline cellulose, cyclodextrin, methylated cyclodextrin, light anhydrous silicic acid, synthetic aluminum silicate, and magnesium aluminate metasilicate and tritoqualin. A liver disease therapeutic drug composition obtained by.
化シクロデキストリン、軽質無水ケイ酸、合成ケイ酸ア
ルミニウム及びメタケイ酸アルミン酸マグネシウムより
なる群から選ばれる１種又は２種以上の使用量がトリト
クアリン１重量部に対して１〜１０重量部であることを
特徴とする特許請求の範囲第１項記載の組成物。(2) The usage amount of one or more selected from the group consisting of crystalline cellulose, cyclodextrin, methylated cyclodextrin, light anhydrous silicic acid, synthetic aluminum silicate, and magnesium aluminate metasilicate is 1 part by weight of tritoqualin. The composition according to claim 1, characterized in that the amount is 1 to 10 parts by weight based on the composition.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25965086A JPS63115815A (en) | 1986-10-31 | 1986-10-31 | Hepatic disease remedy composition |
| PCT/JP1987/000829 WO1988003023A1 (en) | 1986-10-31 | 1987-10-29 | Drug composition for treating liver diseases and process for its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25965086A JPS63115815A (en) | 1986-10-31 | 1986-10-31 | Hepatic disease remedy composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS63115815A true JPS63115815A (en) | 1988-05-20 |
Family
ID=17336994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP25965086A Pending JPS63115815A (en) | 1986-10-31 | 1986-10-31 | Hepatic disease remedy composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63115815A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997006781A1 (en) * | 1995-08-11 | 1997-02-27 | Nissan Chemical Industries, Ltd. | Methods for making hardly soluble medicine amorphous |
| WO1997040828A1 (en) * | 1996-04-26 | 1997-11-06 | Shionogi & Co., Ltd. | Rapid-release s1452 tablets |
| WO2000071117A1 (en) * | 1999-05-21 | 2000-11-30 | Kissei Pharmaceutical Co., Ltd. | Immediate release medicinal compositions for oral use |
| EP1308156A4 (en) * | 2000-08-11 | 2009-07-15 | Eisai R&D Man Co Ltd | Drug-containing solid dispersion having improved solubility |
-
1986
- 1986-10-31 JP JP25965086A patent/JPS63115815A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997006781A1 (en) * | 1995-08-11 | 1997-02-27 | Nissan Chemical Industries, Ltd. | Methods for making hardly soluble medicine amorphous |
| US6462093B1 (en) | 1995-08-11 | 2002-10-08 | Nissan Chemical Industries, Ltd. | Method for converting sparingly water-soluble medical substance to amorphous state |
| WO1997040828A1 (en) * | 1996-04-26 | 1997-11-06 | Shionogi & Co., Ltd. | Rapid-release s1452 tablets |
| US6056974A (en) * | 1996-04-26 | 2000-05-02 | Shionogi & Co., Ltd. | Rapid-release S1452 tablets |
| WO2000071117A1 (en) * | 1999-05-21 | 2000-11-30 | Kissei Pharmaceutical Co., Ltd. | Immediate release medicinal compositions for oral use |
| US7160555B2 (en) | 1999-05-21 | 2007-01-09 | Kissei Pharmaceutical Co., Ltd. | Immediate release medicinal compositions for oral use |
| US7160556B2 (en) | 1999-05-21 | 2007-01-09 | Kissei Pharmaceutical Co., Ltd. | Immediate release medicinal compositions for oral use |
| US7166301B1 (en) | 1999-05-21 | 2007-01-23 | Kissei Pharmaceutical Co., Ltd. | Immediate release medicinal compositions for oral use |
| EP1308156A4 (en) * | 2000-08-11 | 2009-07-15 | Eisai R&D Man Co Ltd | Drug-containing solid dispersion having improved solubility |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1306686C (en) | Pharmaceutical composition containing ibuprofen | |
| US4859709A (en) | Pharmaceutical composition | |
| EP2101733B1 (en) | Powder formulation for valganciclovir | |
| GB2139892A (en) | Solid pharmaceutical preparation containing nifedipine | |
| JPH0714876B2 (en) | Therapeutic composition containing fenofibrate and method for producing the same | |
| JPS5914446B2 (en) | Solid preparation containing nifedipine and its manufacturing method | |
| JP2001525820A (en) | Topical composition | |
| EP3749286A1 (en) | A pharmaceutical composition comprising metamizole, drotaverine, and caffeine | |
| PL194847B1 (en) | Method for preparing novel fenofibrate galenic formulations, galenic formulations obtained and applications | |
| JPH07196512A (en) | Medicinal composition | |
| JPH05952A (en) | Tolasemide-containing medicinal composition | |
| TW509570B (en) | A stable cilansetron pharmaceutical preparation method for anti-racemization | |
| JPS63115815A (en) | Hepatic disease remedy composition | |
| TWI286072B (en) | Sleeping medicine formed by coating solid | |
| JP5563260B2 (en) | Pharmaceutical preparations containing poorly soluble drug substances | |
| EP2101742B1 (en) | Pharmaceutical composition containing clopidogrel hydrogenesulphate of polymorph 1 form | |
| DE3602577A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING 9,10-DIHYDROGENATED ERGOTAL CALOIDS | |
| JPH07165561A (en) | Preparation of laxative composition | |
| JPS6067425A (en) | Carcinostatic agent | |
| JPS6138170B2 (en) | ||
| CA2469736A1 (en) | Diphenhydramine tannate solid dose compositions and methods of use | |
| JPH09309829A (en) | Oral administration preparation containing nitrendipine and its production | |
| US4804540A (en) | Process for preparing the combination products of triamterene and hydrochlorothiazide | |
| US4054658A (en) | Therapeutic compositions containing methaqualone | |
| JPS5824514A (en) | Remedy for peptic ulcer |